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Background: Many patients with chronic cough respond to treatment with inhaled corticosteroids but it is difficult to
predict which patients are likely to respond. The primary aim of the present study was to define the capability of
hypertonic saline cough provocation test to predict the responsiveness to inhaled corticosteroids in chronic cough. The
secondary aim was to assess the ability of the saline test to monitor the healing of cough during corticosteroid treatment.
Methods: Forty-three patients with chronic cough were recruited. Before therapy, spirometry, ambulatory peak flow
monitoring, nitric oxide measurement, histamine airway challenge, and saline test were performed. Those responding
to the first saline test repeated it and the nitric oxide measurement during the subsequent visits. The patients used
inhaled budesonide, 400 ug twice daily, for twelve weeks. The treatment response was assessed by Leicester Cough
Questionnaire at baseline, and at one, four, and twelve weeks.
Results: Seventy-seven % of the patients demonstrated the minimal important difference in the Leicester Cough
Questionnaire indicating a symptomatic response. Neither the response magnitude nor the speed was predicted by
the saline test. Histamine challenge showed the strongest predictive ability: The maximal improvement in Leicester
Cough Questionnaire total score was 5.08 (3.76 – 6.40) points in the histamine positive and 2.78 (1.55 – 4.01) points in
the histamine negative subjects (p = 0.006). Baseline nitric oxide level also associated with the improvement in
Leicester Cough Questionnaire total score (p = 0.02). During the treatment, the cough sensitivity to saline gradually
decreased among the budesonide responders but not in the non-responders. Nitric oxide levels decreased very rapidly
among the responders.
Conclusions: Saline test cannot predict the responsiveness to inhaled corticosteroids in chronic cough but it may be
utilized to monitor the effect of this treatment.
Trial registration: The study was registered in ClinicalTrials.gov database (KUH5801112). ClinicalTrials.gov
Identifier: NCT00859274
Keywords: Chronic cough, Inhaled corticosteroids, Cough provocation tests, Airway hyperresponsiveness, Nitric oxideBackground
Chronic cough is reported by 10 – 20% of general
population [1]. Current guidelines on chronic cough
suggest defining the underlying medical condition and
specific treatment directed at it [1-3]. However, often the
underlying condition cannot be identified and treatment* Correspondence: heikki.koskela@kuh.fi
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distribution, and reproduction in any mediumtrials based on the most probable cause are recommended.
In about 30% of chronic cough patients there is a
corticosteroid-sensitive airway inflammation without
objective evidence of asthma. Therefore, a trial of inhaled
corticosteroids (ICS) in all patients with chronic cough
has been recommended [1]. Given the high number of
such patients this leads to a large amount of unsuccessful
trials. A test capable to identify patients who are likely to
benefit from ICS would be valuable.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 The basic characteristics of 43 patients with
chronic cough
Age (years) 55.6 (51.9 – 59.4)
Number of females 32 (74%)
Body mass index (kg/m2) 27.4 (25.8 – 29.0)
Number of ex smokers 20 (47%)
Number of atopic patients 14 (33%)
Duration of cough (years) 8.5 (5.5 – 11.6)
Most probable cause of cougha Rhinitis 22 (51%)
Esophageal reflux 14 (33%)
Asthma 9 (21%)
Leicester questionnaire total score 13.2 (12.2 – 14.3)
Saline coughs-to-dose ratio (coughs/Osm/kg) 7.24 (5.16 – 9.33)
Number of saline responders 21 (49%)
Histamine response-to-dose ratiob (%/mg) 7.94 (4.74 – 13.3)
Number of histamine respondersc 21 (50%)
Nitric oxide concentration (ppm) 16.8 (12.7 – 20.9)
FEV1 (% of predicted) 93.7 (90.2 – 97.3)
FEV1 rise after salbutamol (%) 4.05 (2.86 – 5.24)
PEF variation in ambulatory monitoring (%) 7.13 (5.76 – 8.51)
a Based on the results of the Cough Clinic diagnostic questionnaire. Two
patients had more than one most probable cause; b geometric mean and 95%
confidence interval; c histamine challenge was missed in one patient due to
technical reasons.
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nitric oxide (NO) levels have been shown to predict the
response to a two-week treatment with ICS in patients
with chronic cough [4,5]. A later, retrospective study
suggested that elevated NO might even predict a
months-long response to ICS in these patients [6].
However, the most recent, prospective study failed to
confirm these findings [7]. In that study, neither NO,
methacholine challenge, nor adenosine challenge could
predict the response to a four-week treatment with inhaled
fluticasone 200 ug daily. All the above-mentioned
prospective studies may be criticized for short duration
and lack of a pre-determined, well validated end point to
define a positive clinical response.
Cough provocation tests with hypertonic aerosols are
novel types of cough provocation tests. They act via
different pathways than the traditional cough tests with
capsaicin and citric acid which are capable to stimulate
the major sensory receptor for cough, the transient receptor
potential vanilloid subfamily member 1 [8]. The cough
response to hypertonic aerosols does not involve this
receptor [9,10]. The cough sensitivity to hypertonic
aerosols is associated with asthma [11-15] and treatment
with ICS attenuates the cough sensitivity to them [11]. In
asthma, cough sensitivity to hypertonic saline correlates
well with the Leicester Cough Questionnaire and with
the Juniper’s Asthma Control Questionnaire [16]. Thus,
responsiveness to hypertonic saline cough provocation test
can be regarded as a valid measure in asthma-associated
cough. We therefore hypothesized that this test might
predict the responsiveness to ICS treatment in chronic
cough. Secondly, we hypothesized that changes in the
responsiveness to hypertonic saline during treatment
might reflect the healing of cough. The present study was
planned to test these hypotheses.
Methods
Subjects
Forty-three subjects with chronic cough of at least
eight weeks’ duration were recruited using newspaper
advertisements. Exclusion criteria were current smoking,
any abnormalities in chest x-ray, a febrile respiratory tract
infection within six weeks, and a doctor’s diagnosis of
asthma. Table 1 shows the characteristics of the subjects.
Five subjects did not complete the study. One dis-
continued due to suspected budesonide allergy and one
due to mild pneumonia. Three subjects did not define a
reason for discontinuation. In addition, three subjects
were found to have non-satisfactory drug compliance.
The 39 subjects who remained in the study for at least four
weeks with satisfactory drug compliance were included in
the final analysis.
The study was performed in accordance with the
Good Clinical Practice guidelines recommended bythe Declaration of Helsinki. The study was approved
by the institutional Ethics Committee (132//2008) as
well as the National Agency for Medicines (EudraCT
2009-009556-21). Written informed consent was obtained
from each subject prior to participation in the study.
Study design
This was a prospective, open-label study. On the first
study day the subject was interviewed, the informed
consent was obtained, and the Cough Clinic diagnostic
questionnaire was filled in [17]. It is a validated question-
naire to assess the most probable cause of cough. Further-
more, a chest x-ray, skin prick tests and histamine airway
challenge were performed [18]. The histamine challenge
was considered positive if the provocative dose of histamine
to produce a 15% fall in forced expiratory volume in one
second (FEV1) was less than 1.6 mg. The histamine
response-to-dose ratio (RDR) was calculated as the final
percentage fall in FEV1 divided by the final non-cumulative
dose of histamine. A peak expiratory flow (PEF) monitoring
twice daily was performed during the week between the
first and the second study day.
On the second study day the Leicester Cough Question-
naire [19] (LCQ) was filled in, NO was measured according
to international guidelines [20] using a chemiluminescence
analyzer (Sievers Model 280 NOA; Sievers Instruments,
Inc., Boulder, CO, USA), and the hypertonic saline cough
Figure 1 The changes in Leicester Cough Questionnaire (LCQ)
total score during treatment with inhaled budesonide among
chronic cough patients who either did or did not respond to
histamine challenge at baseline. ** p < 0.01, Mann–Whitney U test.
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weeks, the subjects used budesonide inhalation powder
400 ug twice a day (Budesonid Easyhaler, Orion Ltd,
Espoo, Finland). The drug compliance was assessed on
each subsequent visit utilizing the counter of the inhaler.
A satisfactory compliance was defined as more than 50%
usage of the prescribed dose.
The third, fourth and fifth study days took place when
the subjects had used budesonide for one, four, and
twelve weeks, respectively. During these days the LCQ was
filled in. In addition, those subjects who were responsive to
the first saline test repeated it and the NO measurement
during these days.
Leicester cough questionnaire and the definitions of
treatment responses
The Leicester Cough Questionnaire (LCQ) is a 19-item
validated, repeatable and responsive questionnaire consisting
of physical, psychological and social domains. Answers are
graded on 7-point Likert scale which gives a total score
ranging from 3 to 21. A small score indicates poor
cough-related quality of life [19].
The minimal important difference of LCQ total score
is 1.3 points [21]. Documentation of it at any time point
during the budesonide treatment was defined as a positive
treatment response. The magnitude of the budesonide
response was expressed by the maximal improvement in
LCQ total score at any time point of the treatment. The
speed of the budesonide response was expressed by the
time from the start of treatment to the appearance of
minimal important difference in LCQ total score, utilizing
linear interpolation. If the minimal important difference
was never achieved, an arbitrary value of 16 weeks was
utilized for statistical purposes.
Hypertonic saline cough provocation test
The test has been described in detail previously [13]. First,
spirometry was performed. Then the subjects inhaled
0.4 mg of salbutamol to prevent bronchoconstriction.
Fifteen minutes after the salbutamol inhalation the
spirometry was repeated. Then the subject inhaled isotonic
phosphate-buffered saline for two minutes via a high-
output ultrasonic nebuliser (DeVilbiss Ultraneb 3000,
Sunrise Medical Ltd, West Midlands, UK), using tidal
breathing. The coughs occurring during the inhalation
and two minutes after it were counted up. The number
of these “spontaneous” coughs was subtracted from the
coughs provoked by each hypertonic solution. Subse-
quently, they inhaled hypertonic phosphate-buffered saline
solutions with osmolalities of 0.6, 0.9, 1.2, 1.5, 1.8 and
2.1 Osm/kg. The challenge was stopped if 15 or more
cumulative coughs were recorded (= a positive saline test
result). The cough sensitivity to hypertonic saline was
expressed as coughs-to-dose-ratio (CDR), calculated asthe cumulative number of provoked coughs divided by the
final osmolality inhaled.Statistical analysis
The sample size requirement for this study was calculated
considering clinically relevant a difference of 45% in the
proportion of patients responsive to budesonide treatment
between the groups with positive and negative saline test
result. The calculation was based on previous studies
about the prevalence of positive saline tests among patients
with chronic cough and the responsiveness of these
patients to ICS [7,13]. It was estimated that 42 patients
would be required to provide 80% power at the 0.05 level.
The data is expressed as means and 95% confidence
intervals. The histamine RDR values and the speed of
the budesonide response are expressed as geometric
means and 95% confidence intervals. Chi-square test,
Friedman’s analysis of variance, Mann–Whitney U test
and Spearman correlation coefficient were utilized when
appropriate.Results
The baseline test results
The patients with asthma as the most probable cause of
cough were more sensitive to saline than the rest of the
patients (11.2 (6.77 – 15.6) coughs/Osm/kg vs. 6.20
(3.86 – 8.55) coughs/Osm/kg, p = 0.034). There were no
other differences in baseline test results between the
diagnostic categories (Table 1). Furthermore, there were
no significant correlations between LCQ total score or
saline CDR and the other tests.
Table 2 The responses to the budesonide treatment in 39 chronic cough patients divided by the baseline saline
and histamine test results
Baseline saline test Baseline histamine challengea
Negative p Positive Negative p Positive
(N = 19) (N = 20) (N = 19) (N = 19)
Response magnitude (points) 4.45 (2.95 – 5.94) 0.50 3.61 (2.37 – 4.85) 2.78 (1.55 – 4.01) 0.006 5.08 (3.76 – 6.40)
Response speedb (weeks) 1.34 (0.60 – 2.98) 0.72 1.46 (0.68 – 3.15) 2.70 (1.23 – 5.93) 0.008 0.72 (0.36 – 1.43)
Response magnitude was defined as the maximal improvement in LCQ total score at any time point of the study. Response speed was defined as the time in
weeks from the start of budesonide treatment to the appearance of minimal important change in LCQ total score.
aHistamine challenge was missed in one subject due to technical reasons.
bGeometric means and 95% confidence intervals.
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The mean compliance (the mean amount of inhaled
doses in relation to prescribed doses) was 92%. The
response was rapid in those eventually responding to
the treatment (Figure 1). The minimal important
change in the LCQ was achieved by 77% of the
subjects. Those with rhinitis as the most probable
cause of cough tended to show a larger (p = 0.097)
and faster (p = 0.016) response to budesonide than the
rest of the patients.Baseline tests as predictors of the response to
budesonide treatment
The saline test predicted neither the magnitude nor the
speed of the budesonide response (Tables 2 and 3).
Seventy-five % of the saline test positive and 79% of the
test negative subjects demonstrated the minimal important
difference in the LCQ total score (p = 0.77). The most
important predictor of the treatment response was the
histamine challenge result (Tables 2 and 3, Figure 1). NO
also showed some predictive value but the spirometric
indices and the PEF variability none.Table 3 Associations of the baseline test results with the






Saline CDR Rs = -0.09, p = 0.59 Rs = 0.12, p = 0.45
Nitric oxide level Rs = 0.37, p = 0.020 Rs = -0.31, p = 0.055
Histamine RDRa Rs = 0.47, p = 0.003 Rs = -0.49, p = 0.002
FEV1 Rs = -0.16, p = 0.32 Rs = 0.23, p = 0.17
FEV1 rise after salbutamol Rs = 0.10, p = 0.55 Rs = -0.12, p = 0.48
Mean PEF variation Rs = 0.18, p = 0.28 Rs = -0.21, p = 0.19
a Histamine challenge was missed in one subject due to technical reasons.
Rs Spearman correlation coefficient.
Magnitude of the response was defined as the maximal improvement in
LCQ total score at any stage of the treatment. Speed of the response
was defined as the time in weeks from the start of budesonide
treatment to the appearance of minimal important change in LCQ
total score.Changes in saline CDR and NO during budesonide treatment
and their associations with the changes in LCQ total score
The saline CDR diminished slowly but significantly, from
13.3 (11.3 – 15.3) coughs/Osm/kg before the treatment to
5.65 (3.14 – 8.15) coughs/osm/kg after the 12 weeks’ treat-
ment (p < 0.001, Friedman’s test). This decline in saline
sensitivity was restricted to symptomatic responders
(Figure 2). After twelve weeks’ treatment, the saline CDR
was significantly lower in the responders than in the non-
responders (3.04 (0.84 – 5.24) vs. 10.9 (7.36 – 14.4),
p < 0.001). At that stage, the change in saline CDR
associated with the change in the LCQ total score
(Table 4).
There was also a statistically significant change in NO,
from 20.0 (11.1 – 28.9) ppm before treatment to 12.8
(10.2 – 15.3) ppm after 12 weeks’ treatment (p = 0.037,
Friedman’s test). This decline in NO could be demon-
strated only in the symptomatic responders and was very
rapid among them (Figure 3). There was a significant
association between the drop in NO and a rise in LCQ
total score after one week’s treatment (Table 4).Figure 2 The cough sensitivity to hypertonic saline during
treatment with inhaled budesonide among cough patients who
either did or did not show a symptomatic response to the
treatment. The response was defined at each time point as a more than
1.3 points’ increase from baseline in Leicester Cough Questionnaire total
score. CDR = coughs-to-dose ratio. *** p < 0.001, Mann–Whitney U test.
Table 4 Associations of the change in LCQ total score
with the changes in exhaled NO concentration and saline
CDR at various stages of budesonide treatment
Duration of treatment Change in NO Change in saline CDR
1 week Rs = -0.47, p = 0.038 Rs = 0.37, p = 0.11
4 weeks Rs = -0.40, p = 0.084 Rs = -0.27, p = 0.26
12 weeks Rs = -0.39, p = 0.11 Rs = -0.45, p = 0.059
Rs Spearman rank correlation coefficient.
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In the present study a positive response to budesonide
treatment was defined as the minimal important difference
in the highly validated LCQ. This clinically relevant end
point was achieved by 77% of the patients corroborating
that a substantial proportion of chronic cough patients
benefit from ICS [5,7]. However, neither the magnitude
nor the speed of the budesonide response could be
predicted by the cough sensitivity to hypertonic saline.
This was surprising since cough sensitivity to hypertonic
aerosols has been shown to associate with asthma in
several previous studies [11-15]. Furthermore, the cough
patients who were classified as probable asthmatics by the
Cough Clinic questionnaire in the present study were
more sensitive to saline than the rest of the patients.
As asthma is a corticosteroid-sensitive disorder, one
would have expected that cough sensitivity to hypertonicity
could predict the corticosteroid response. The present
negative finding suggests that cough sensitivity to
hypertonicity is not directly related to the eosinophilic
(corticosteroid-sensitive) airway inflammation. Indeed,
there was no correlation between saline CDR and
NO in the present study, corroborating our previous
findings [13].Figure 3 The exhaled nitric oxide levels during treatment with
inhaled budesonide among cough patients who either did or
did not show a symptomatic response to the treatment. The
response was defined at each time point as a more than 1.3 points’
increase from baseline in Leicester Cough Questionnaire total score.Airway responsiveness to histamine was clearly the
strongest predictor of the budesonide response. This is
contrary to the sole previous study about this issue
[7]. In that study, neither methacholine nor adenosine
responsiveness could predict the response to a four-week
treatment with inhaled fluticasone among 43 patients with
chronic cough [7]. This discrepancy is probably due to the
fact that only four patients responded to methacholine
and two to adenosine in that study. In the present study
half of the cough patients responded to histamine. Airway
hyperresponsiveness often accompanies chronic cough [18]
but its prevalence seems to vary considerably in different
cough populations. The patients in the previous study had
been referred to special respiratory clinics and those with
airway hyperresponsiveness may have been identified
already in primary health care level. Instead, the patients
of the present study were recruited utilizing newspaper
advertisements and enrolled without selection. These
findings suggest that measurement of airway responsiveness
might be most beneficial at an early stage in the
evaluation of chronic cough. Of note, the level of histamine
responsiveness in the present cough patients was much
milder than that usually found among asthmatic patients
[18]. It seems that even mild airway hyperresponsiveness
in a cough patient advocates a trial with ICS.
Exhaled NO concentration also showed some value in
predicting the response to budesonide. The previous
literature about this issue is conflicting [5-7]. This may
be due to similar reasons to those discussed in the previous
paragraph. If the cough population contains very few
subjects with elevated NO, it cannot predict the response
to ICS [7].
The subjects who showed the greatest benefit from
inhaled budesonide in the present study were often
classified as rhinitic patients by the Cough Clinic diagnostic
questionnaire [17]. One explanation for this unexpected
finding may be that the ability of this questionnaire to
identify the underlying reason for chronic cough is worse
than anticipated. Perhaps a more likely explanation is
that chronic rhinitis and asthma can be regarded as
manifestations of the same disorder (the one-airway
hypothesis) [22]. Among patients with chronic cough
and symptoms suggestive of either rhinitis or asthma, an
interesting management option might be a concomitant
treatment with both nasal and inhaled corticosteroids,
or administration of inhaled corticosteroid through the
nose [23].
The second aim of the present study was to evaluate
saline test and NO measurement in their capability for
monitoring the effect of ICS therapy in chronic cough.
These two biomarkers behaved very differently in this
respect.
After just one week’s therapy a drop in NO levels
could be demonstrated among patients with a positive
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among asthmatics that NO levels very rapidly respond
to ICS and highlights the high sensitivity of eosinophilic
inflammation to corticosteroids [24]. The decrease in
NO reflected the healing of cough because it could only
be seen in the budesonide responders and the changes
in NO showed an association with the changes in LCQ
total score after one week’s treatment. These findings,
together with previous studies [4,5], suggest that NO
best predicts the short-term response to ICS in chronic
cough.
Saline CDR, in turn, decreased slowly. The difference
between responders and non-responders was statistically
significant not until 12 weeks’ treatment. The decrease in
saline CDR also reflected the healing of cough because it
could only be seen in the budesonide responders and the
changes in CDR showed an association with the changes
in LCQ total score after 12 weeks’ treatment.
The time course of the decrease in saline cough
responsiveness was similar to the attenuation of the
cough responsiveness to mannitol during treatment with
ICS [11]. Mannitol is another hypertonic agent. In
asthma, the decrease in the cough responsiveness to
mannitol is apparent after three months’ ICS therapy but
continues to decrease up to six months. The decrease in
cough responsiveness to mannitol associates significantly
with the healing of cough [11]. ICS may also affect the
cough sensitivity to capsaicin and citric acid but the
results are conflicting [25-28]. The decrease in cough
responsiveness to hypertonic aerosols during ICS treatment
possibly represents a slow de-sensitization of the airway
sensory nerves as the levels of inflammation- and oxidative
stress-associated mediators, capable to sensitize sensory
nerves, decrease [29,30].
The main limitation of the present study is its un-
controlled nature. The large proportion of budesonide
responders may be partly explained by the placebo effect
and/or the regression-to-mean phenomenon. The latter
may be unlikely because the subjects had suffered from
cough for a very long time, mean 8.5 years. The main
strengths of the present study are, compared to the previous
prospective studies about this issue [4,5,7], the well
validated indicator of the treatment response and the
longer duration of the treatment. The non-selected
population may also be regarded as strength.
Conclusions
The present study confirms that a large proportion of
patients with chronic cough benefits from ICS treatment.
However, the responsiveness to ICS cannot be predicted
by the hypertonic saline cough provocation test. In the
present non-selected cough population, responsiveness to
histamine airway challenge was the strongest predictive
feature of the ICS response. Both the saline test and NOmeasurement might be used to monitor the effect of an
anti-inflammatory treatment in chronic cough. These tests
probably measure different pathophysiological phenomena
and therefore, provide complementary information about
the healing of cough.
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